TITLE

Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial

AUTHOR(S)
Pomat, William S.; van den Biggelaar, Anita H. J.; Phuanukoonnon, Suparat; Francis, Jacinta; Jacoby, Peter; Siba, Peter M.; Alpers, Michael P.; Reeder, John C.; Holt, Patrick G.; Richmond, Peter C.; Lehmann, Deborah
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Approximately 826,000 children, mostly young infants, die annually from invasive pneumococcal disease. A 6-10-14-week schedule of pneumococcal conjugate vaccine (PCV) is efficacious but neonatal PCV may provide earlier protection and better coverage. We conducted an open randomized controlled trial in Papua New Guinea to compare safety, immunogenicity and priming for memory of 7-valent PCV (PCV7) given in a 0-1-2-month (neonatal) schedule with that of the routine 1-2-3-month (infant) schedule. Methods: We randomized 318 infants at birth to receive PCV7 in the neonatal or infant schedule or no PCV7. All infants received 23-valent pneumococcal polysaccharide vaccine (PPV) at age 9 months. Serotype-specific serum IgG for PCV7 (VT) serotypes and non-VT serotypes 2, 5 and 7F were measured at birth and 2, 3, 4, 9, 10 and 18 months of age. Primary outcomes were geometric mean concentrations (GMCs) and proportions with concentration ≥0.35 µg/ml of VT serotype-specific pneumococcal IgG at age 2 months and one month post-PPV. Results: We enrolled 101, 105 and 106 infants, respectively, into neonatal, infant and control groups. Despite high background levels of maternally derived antibody, both PCV7 groups had higher GMCs than controls at age 2 months for serotypes 4 (p<0.001) and 9V (p<0.05) and at age 3 months for all VTs except 6B. GMCs for serotypes 4, 9V, 18C and 19F were significantly higher (p<0.001) at age 2 months in the neonatal (one month post-dose2 PCV7) than in the infant group (one month post-dose1 PCV7). PPV induced significantly higher VT antibody responses in PCV7-primed than unprimed infants, with neonatal and infant groups equivalent. High VT and non-VT antibody concentrations generally persisted to age 18 months. Conclusions: PCV7 is well-tolerated and immunogenic in PNG neonates and young infants and induces immunologic memory to PPV booster at age 9 months with antibody levels maintained to age 18 months. Trial Registration: ClinicalTrials.gov NCT00219401NCT00219401
ACCESSION #
87624847

 

Related Articles

  • Antipneumococcal Seroprevalence and Pneumococcal Carriage During a Meningococcal Epidemic in Burkina Faso, 2006. Yaro, Seydou; Njanpop-Lafourcade, Berthe-Marie; Drabo, Aly; Idohou, Régina S.; Kroman, Sita S.; Sanou, Oumarou; Traoré, Yves; Sangaré, Lassana; Diagbouga, Serge P.; Koeck, Jean-Louis; Borrow, Raymond; Gessner, Bradford D.; Mueller, Judith E. // Journal of Infectious Diseases;Apr2014, Vol. 209 Issue 8, p1241 

    Background. To better understand the high incidence of pneumococcal meningitis in the African meningitis belt, we conducted a pneumococcal seroprevalence study during a meningococcal meningitis epidemic in Western Burkina Faso, March 2006.Methods. In 3 villages experiencing epidemics, we...

  • Correction: Vol. 21, No. 11.  // Emerging Infectious Diseases;Jan2016, Vol. 22 Issue 1, p161 

    A correction to the article "Invasive Pneumococcal Disease 3 Years After Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands," in a previous issue is presented.

  • Characterization of Protective Immune Responses Induced by Pneumococcal Surface Protein A in Fusion with Pneumolysin Derivatives. Goulart, Cibelly; Silva, Thais Raquel da; Rodriguez, Dunia; Politano, Walter Rodrigo; Leite, Luciana C. C.; Darrieux, Michelle // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candidates, which can confer protection in different models of pneumococcal infection. Furthermore, the combination of these two proteins was able to increase protection against pneumococcal sepsis in...

  • Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children. Ayieko, Philip; Griffiths, Ulla K.; Ndiritu, Moses; Moisi, Jennifer; Mugoya, Isaac K.; Kamau, Tatu; English, Mike; Scott, J. Anthony G. // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. We estimated the cost-effectiveness of introducing either PCV10 or the13-valent vaccine (PCV13) from a societal perspective and explored the incremental impact of including indirect...

  • Herd effect of PCV7 in children reduced pneumococcal carriage in Gambia.  // Infectious Diseases in Children;Jan2012, Vol. 25 Issue 1, p7 

    The article discusses a randomized trial study conducted by the Medical Research Council Unit in Gambia, Africa which revealed a herd effect of 7-valent pneumococcal conjugate vaccine (PVC7) treatment in reducing pneumococcal nasopharyngeal carriage in nonvaccinated older children and adults.

  • Recurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia. Ballegaard, Vibe C.; Schejbel, Lone; Hoffmann, Steen; Kantsø, Bjørn; Fischer, Christian P. // BMC Infectious Diseases;2015, Vol. 15 Issue 1, p1 

    Background: The risk of life-threatening and invasive infections with encapsulated bacteria is increased in patients with hyposplenia or asplenia. We report a case of recurrent invasive pneumococcal meningitis in a woman with previous unknown hyposplenia. She was vaccinated after the first...

  • Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV-Infected Adults with a Toll-Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial. Søgaard, Ole S.; Lohse, Nicolai; Harboe, Zitta B.; Offersen, Rasmus; Bukh, Anne R.; Davis, Heather L.; Schønheyder, Henrik C.; Østergaard, Lars // Clinical Infectious Diseases;7/1/2010, Vol. 51 Issue 1, p42 

    Background. Persons infected with human immunodeficiency virus (HIV) are often hyporesponsive to immunization, including pneumococcal vaccines. We hypothesized that adding CPG 7909, a toll-like receptor 9 (TLR9) agonist and vaccine adjuvant, to 7-valent pneumococcal conjugate vaccine (7vPnC)...

  • Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. Kasanmoentalib, E. Soemirien; Seron, Mercedes Valls; Morgan, B. Paul; Brouwer, Matthijs C.; van de Beek, Diederik // Journal of Neuroinflammation;Aug2015, Vol. 12 Issue 1, p1 

    Background: We compared adjunctive treatment with placebo, dexamethasone, anti-C5 antibodies, and the combination of dexamethasone plus anti-C5 antibodies in experimental pneumococcal meningitis. Methods: In this prospective, investigator-blinded, randomized trial, 96 mice were infected...

  • Age-related changes in human peripheral blood IGH repertoire following vaccination. Yu-Chang Bryan Wu; Kipling, David; Dunn-Walters, Deborah K. // Frontiers in Immunology;Jun2012, Vol. 3, p1 

    Immune protection against pulmonary infections, such as seasonal flu and invasive pneumonia, is severely attenuated with age, and vaccination regimes for the elderly people often fail to elicit effective immune response. We have previously shown that influenza and pneumococcal vaccine responses...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics